Back to Results

Alexion TMAS

Title A study to evaluate the efficacy and safety of Ravulizumab (ALXN1210) in patients with Thrombotic Microangiopathy (TMA) associated with a trigger 
Therapeutic Area Thrombotic Microangiopathy (TMA), Kidney Diseases
Principal Investigator Craig E. Gordon MD, MS
Min Age 18 Years
Gender All
Contact Jasmine Pak
More Information


The purpose of this trial is to see if the drug ravulizumab  is safe and effective in patients with thrombotic microangiopathy (TMA). This study is double-blind and placebo-controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a saline solution. There is a 50% chance that you will recieve the drug. You will recieve the drug or placebo for about 6 months and then have follow-up appoinments for about 6 months. 

Study Details

Inclusion Criteria

  • Diagnosis of TMA

Exclusion Criteria

  • History of cancer <5 years ago (with some exceptions)
  • Known chronic kidney disease with estimated GFR <45 mL/min/1.73^2

Study Requirements

This study involves a screening visit, 13 visits during the 26 week treatment period, and 3 visits during the 26 week follow up period. Some study visits include blood draws and urine collections. No x-rays/CT scans/MRIs are required by the study.